Dual-platform assay improves equine famotidine-omeprazole analysis
Bottom line
Researchers in South Korea reported a new dual-platform bioanalytical approach for measuring famotidine and omeprazole in equine plasma, aiming to solve a familiar lab problem: the two drugs behave very differently during sample preparation and analysis. In a Frontiers in Veterinary Science study published September 7, 2026, the team showed that acidifying samples helped resolve famotidine peak-splitting and improved omeprazole linearity in HPLC, while a separate pH-neutral UHPLC-MS/MS workflow protected acid-labile omeprazole and enabled trace-level quantification of omeprazole and its metabolite, omeprazole sulfone. The UHPLC-MS/MS method achieved a lower limit of quantification of 50 ng/mL, which the authors said was about 2,000 times more sensitive than the HPLC method, and the platform was then used to generate concentration-time profiles and pharmacokinetic parameters in treated racehorses. (frontiersin.org)
Why it matters: For veterinary professionals, this is less about a new treatment than a better measurement tool for drugs already central to equine gastric disease management. Omeprazole remains the best-studied acid suppressant and the drug of choice for equine gastric ulcer syndrome, while H2-receptor antagonists such as famotidine work through a different mechanism and may be used alongside or instead of proton pump inhibitors in some settings. Better analytical methods could make future pharmacokinetic, formulation-comparison, withdrawal, and drug-interaction studies more reliable, especially because omeprazole is acid labile, formulation-sensitive, and known to show variable bioavailability in horses. (academic.oup.com)
What to watch: Watch for follow-up studies using this assay framework to test co-administration strategies, compare formulations, or support racing medication-control and withdrawal research in horses. (frontiersin.org)
Key facts
- Study type
- Frontiers in Veterinary Science methods study
- Publication date
- September 7, 2026
- Species
- Equine plasma
- Drugs measured
- Famotidine and omeprazole
- Analytical approach
- Complementary HPLC and pH-neutral UHPLC-MS/MS
- Main HPLC issue
- Famotidine peak-splitting and omeprazole nonlinearity
- UHPLC-MS/MS sensitivity
- Lower limit of quantification, 50 ng/mL
- Relative sensitivity
- About 2,000 times more sensitive than HPLC
- Study application
- Used to generate concentration-time profiles and pharmacokinetic parameters in treated racehorses
A new equine pharmacology paper argues that sometimes one analytical platform isn't enough. In a Frontiers in Veterinary Science study published September 7, 2026, investigators described a complementary HPLC and UHPLC-MS/MS strategy for simultaneously quantifying famotidine and omeprazole in equine plasma, designed to overcome matrix effects, solubility issues, and omeprazole's acid instability. The method was then applied to plasma samples from racehorses to characterize pharmacokinetic profiles after drug administration. (frontiersin.org)
The work addresses a practical problem tied to two widely used classes of equine acid-suppressing drugs. Famotidine, an H2-receptor antagonist, and omeprazole, a proton pump inhibitor, act through different mechanisms, making co-administration pharmacologically appealing. At the same time, equine gastric ulcer disease remains common in racehorses, with the paper citing prevalence above 70% and as high as 100% in some cohorts. Existing consensus guidance has long positioned omeprazole as the best-studied and preferred treatment for equine gastric ulcer syndrome, while also noting that formulation, dose, feeding status, and exposure profiles all influence outcomes. (frontiersin.org)
According to the study, the analytical challenge starts with the drugs' chemistry. In HPLC, famotidine showed pH-dependent peak splitting linked to ionization changes, while omeprazole's limited aqueous solubility caused nonlinearity at higher concentrations. The researchers addressed those issues by acidifying the preparation solvent and plasma matrix for HPLC work. But because omeprazole is acid labile, that same strategy isn't suitable for trace-level bioanalysis, so the team built a separate pH-neutral UHPLC-MS/MS method to preserve analyte stability. That second workflow also enabled simultaneous measurement of omeprazole sulfone, a relevant metabolite. (frontiersin.org)
The performance gap between the two platforms was substantial. The authors reported that HPLC was useful for characterizing analytical behavior at relatively high concentrations, but lacked the sensitivity needed for pharmacokinetic work. Their UHPLC-MS/MS assay reached a 50 ng/mL lower limit of quantification, roughly a 2,000-fold sensitivity improvement over HPLC, and was validated before being applied to equine plasma samples. In effect, the paper proposes not a winner between platforms, but a division of labor: HPLC for understanding compound behavior and UHPLC-MS/MS for trace quantification in real pharmacokinetic studies. (frontiersin.org)
Outside this paper, that framing fits the broader equine omeprazole literature. Prior studies have shown that omeprazole pharmacokinetics in horses can vary by formulation and feeding conditions, and regulatory labeling for GastroGard notes marked inter- and intra-subject variability, with food reducing absorption substantially in one pharmacokinetic study. Consensus guidance also highlights that relatively little comparative pharmacokinetic work has been done across formulations, even though those differences may influence clinical response. More recently, pharmacokinetic work on long-acting injectable omeprazole has underscored how assay performance and matrix handling matter when studies are used to inform detection times, screening limits, or product development. (aaep.org)
I didn't find a standalone press release or outside expert quote specifically reacting to this new Frontiers paper. Still, the surrounding literature helps explain why analytical rigor matters here. Reviews and consensus documents repeatedly point to omeprazole's acid lability, formulation dependence, and variable exposure in horses, all of which can complicate interpretation of both clinical and pharmacokinetic data. That makes the paper's platform-specific preparation strategy notable even without broader public commentary yet. (academic.oup.com)
Why it matters: For veterinarians, pharmacologists, and diagnostic labs, this study is a methods advance with downstream clinical value. Better assays can sharpen dose-exposure studies, support comparisons between oral and emerging injectable formulations, and improve confidence in co-administration research involving H2 blockers and PPIs. In equine practice, where treatment response can depend on formulation, feeding management, and disease subtype, stronger bioanalytical tools can help separate true drug effects from artifacts introduced by sample handling or matrix interference. For racing and performance-horse medicine, the same principle could support cleaner pharmacokinetic datasets for medication-control work. (frontiersin.org)
What to watch: The next step is whether other groups adopt this dual-platform framework in larger pharmacokinetic or formulation-comparison studies, especially those examining combined famotidine-omeprazole use, metabolite profiling, or withdrawal-related questions in racehorses. Given the paper was published on September 7, 2026, external validation and real-world uptake will be the key signals to watch over the coming year. (frontiersin.org)